May 4, 2016
Taking ibrutinib at full dose and on schedule improved PFS among patients with chronic lymphocytic leukemia, according to an analysis of the RESONATE trial presented at the Oncology Nursing Society Annual Congress.
“Patients who missed 8 or more consecutive days of ibrutinib oral chemotherapy experienced a higher rate of progression events as opposed to those patients who did not have a drug hold for longer than 1 week," Sarah Deisinger, RN, BSN, told HemOnc Today. “What we can take away from this study, as providers, nurses and other medical professionals, is the critical importance of educating outpatients on oral drug adherence. This includes the ability to be transparent with our patients in regard to treatment outcomes for drug holds greater than 8 days, as well as the effect on PFS.”